A
3.93
0.12 (3.15%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Autolus Therapeutics plc | Bullish | Bullish |
Stockmoo Score
1.1
|
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Syncona Portfolio Ltd | 30 Jun 2024 | 21,346,829 |
| Tfg Asset Management Gp Ltd | 30 Jun 2024 | 8,000,000 |
| Affinity Asset Advisors, Llc | 30 Jun 2024 | 4,300,000 |
| 52 Weeks Range | ||
| Median | 9.00 (129.01%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 17 Jun 2024 | 9.00 (129.01%) | Buy | 4.31 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |